We are live on ! Find out more
HALO icon

Halozyme

325 hedge funds and large institutions have $5.2B invested in Halozyme in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 125 increasing their positions, 115 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $11.4M

9% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 115

0.68% more ownership

Funds ownership: 91.23% → 91.91% (+0.68%)

0% more funds holding

Funds holding: 324 → 325 (+1)

15% less capital inflows, than outflows

Capital inflows: $229M | Capital outflows: $269M

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

29% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 41

Holders
325
Holders Change
+1
Holders Change %
+0.31%
% of All Funds
4.99%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
29
Increased
125
Reduced
115
Closed
41
Calls
$22.7​M
Puts
$11.4​M
Net Calls
+$11.2​M
Net Calls Change
-⁠$2.2​M

HALO Hedge Fund Activity: Q4 2021 in Review

325 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2021, worth a combined $5.2B — down 1.5% from $5.28B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of HALO and 29 opened new positions — a net loss of 12 holders — while 115 trimmed existing stakes and 125 added.

The largest buyer was Snyder Capital Management, adding an estimated $23.8M. The largest seller was Fiera Capital (Canada), exiting entirely with an estimated $24.2M sold.

  • 325 institutional investors held Halozyme (HALO) as of Q4 2021, up from 324 in Q3 2021.
  • Funds reported $5.2B of Halozyme stock for Q4 2021, down 1.5% quarter-over-quarter.
  • 29 funds opened new Halozyme positions in Q4 2021 and 41 closed out, a net change of -12 holders.
  • The largest Halozyme buyer in Q4 2021 was Snyder Capital Management, an estimated $23.8M added.
  • The largest Halozyme seller in Q4 2021 was Fiera Capital (Canada), an estimated $24.2M sold.

Based on aggregated 13F filings for Q4 2021.